Catalyst Wire Dossier Catalyst Wire Dossier

Zevalin (ibritumomab tiuxetan)

ibritumomab tiuxetan
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Zevalin (ibritumomab tiuxetan), covering 2017-11-21 to 2017-11-21. Get the full timeline:

Most recent: Clinical Trial Update: Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma [Phase 2]

See pricing